Atara Biotherapeutics Inc (NAS:ATRA)
$ 10.28 -1.35 (-11.61%) Market Cap: 58.33 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Atara Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 10:15PM GMT
Release Date Price: $359.75 (-6.80%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Tess Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by [Taylor Hanley] from the team.

Our next presenting company is Atara Biotherapeutics, and presenting on behalf of the company, we have CEO, Pascal Touchon. Before I turn it over to Pascal, I just wanted to remind all the listeners to please use the ask a question button in the portal to ask your question, and I'm happy to ask it on your behalf.

With that, I would like to hand it over to Pascal.

Pascal Touchon
Atara Biotherapeutics, Inc. - President, CEO & Director

Thank you, Tess, for the introduction, and thank you to the JPMorgan team for inviting Atara to present. Happy New Year to all of you. I'm very pleased to be here today to tell you more about our industry-leading allogeneic T-cell product pipeline and upcoming catalysts. During the course of my presentation, as you can see on Slide 2, I will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot